FDA Clears TG Therapeutics' Ublituximab For Clinical Trials

TG Therapeutics, Inc. is announcing that the U.S. Food and Drug Administration has cleared the company's Investigational New Drug Application ("IND") for TGTX-1101, also referred to as ublituximab.

TG Therapeutics now intends to initiate a Phase I/II clinical trial in patients diagnosed with B-cell lymphomas, which it says it will do this summer. They intend to recruit up to 36 patients in the Phase I dose escalation component; following that, they hope to recruit up to 77 patients in the Phase II component with B-cell non-Hodgkin's lymphomas (including follicular lymphoma, diffuse large B-cell lymphoma, and other subtypes) who have relapsed, or who have refractory disease following CD20 directed antibody therapy.

"Having only executed the license in late January, we were delighted by the speed at which we were able to file and receive clearance of our first IND," said Michael S. Weiss, Executive Chairman and Interim CEO on learning the news. "We are excited to be able to test ublituximab in B-cell Lymphomas following the high rate of response seen in our original study in relapsed and refractory Chronic Lymphocytic Leukemia."

Ublituximab is a novel, third generation chimeric monoclonal antibody that targets a unique epitope on the CD20 antigen found on B-lymphocytes. It has been bioengineered to be especially effective in triggering an immune response as a single-agent to aid in wiping out a patient's B-cells. It has orphan drug designation in both Europe and in the United States for B-cell Chronic Lymphocytic Leukemia.

Source: MarketWatch

More Articles

More Articles

This article looks at the Non-Hodgkin's Lymphoma survival rate as well as the Non-Hodgkin's Lymphoma mortality rate ....

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

Canine lymphoma is a fairly common cancer in American dogs. The most commonly seen lymphoma in America is a type called Lymphosarcoma, although...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

Marginal zone lymphomas (MZL) are indolent lymphomas that affect the B-cells. The...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

What causes lymphoma is not well known. DNA mutations may be what causes lymphoma to develop but what triggers these mutations is...

Often the one who makes the first diagnosis of Hodgkin's Lymphoma / Disease is the person affected. There are some...

Lymphedema is abnormal swelling due to the presence of excess lymphatic fluid within the tissues. This swelling occurs when the...

RICE is an acronym for an anti-cancer treatment that expresses a combination chemotherapeutic regimen. This regimen is written variously as "R+ICE...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...